FORM OF INDEMNIFICATION AGREEMENTIndemnification Agreement • March 20th, 2013 • Aratana Therapeutics, Inc. • Delaware
THIS INDEMNIFICATION AGREEMENT (this “Agreement”) is made and entered into as of [ ] [ ], 20[ ], by and among Aratana Therapeutics, Inc. (the “Company”) and [ ] (the “Indemnitee”).
ContractLoan and Security Agreement • March 20th, 2013 • Aratana Therapeutics, Inc. • North Carolina
This LOAN AND SECURITY AGREEMENT (the “Agreement”) is entered into as of March 4, 2013, by and between Square 1 Bank (“Bank”) and Aratana Therapeutics, Inc. (“Borrower”).
ARATANA THERAPEUTICS, INC. EMPLOYMENT AGREEMENTEmployment Agreement • March 20th, 2013 • Aratana Therapeutics, Inc. • Delaware
This EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of December 18th, 2012 by and between ARATANA THERAPEUTICS, INC. (the “Company”) and Julia Stephanus (the “Executive”). The Company and the Executive are hereinafter collectively referred to as the “Parties”, and individually referred to as a “Party”.
EXCLUSIVE IP LICENSE AGREEMENT FOR RQ-00000005Exclusive Ip License Agreement • March 20th, 2013 • Aratana Therapeutics, Inc. • New York
This EXCLUSIVE IP LICENSE AGREEMENT FOR RQ-00000005 (this “Agreement”) is entered into as of December 27, 2010 (the “Effective Date”) by and between Aratana Therapeutics Inc., a Delaware corporation having a place of business is 1901 Olathe Boulevard, Kansas City, KS 66103 (“Licensee”) and RaQualia Pharma Inc., a Japanese corporation having a place of business at 5-2 Taketoyo, Aichi 470-2341, Japan (“Licensor”).
SECOND AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENTStockholders’ Agreement • March 20th, 2013 • Aratana Therapeutics, Inc. • Delaware
THIS SECOND AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT (the “Agreement”) is made and entered into as of December 28, 2012, by and among ARATANA THERAPEUTICS, INC., a Delaware corporation (the “Company”), each of the holders of Series C Preferred Stock (as defined below) listed on Exhibit A hereto (the “Series C Preferred Holders”), each of the holders of Series B Preferred Stock (as defined below) listed on Exhibit B hereto (the “Series B Preferred Holders”), each of the holders of Series A Preferred Stock (as defined below) listed on Exhibit C hereto (the “Series A Preferred Holders”), each of the holders of Series A-1 Preferred Stock (as defined below) listed on Exhibit D hereto (the “Series A-1 Preferred Holders” and, together with the Series B Preferred Holders and the Series A Preferred Holders, the “Preferred Holders”), each of the holders of Common Stock (as defined below) listed on Exhibit E hereto (the “Common Holders” and collectively with the Series A Preferred Holders and
SECOND AMENDED AND RESTATED| INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • March 20th, 2013 • Aratana Therapeutics, Inc. • Delaware
THIS SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of December 28, 2012, by and among ARATANA THERAPEUTICS, INC., a Delaware corporation (the “Company”), and the investors set forth on the Schedule of Investors attached hereto as Exhibit A (each, an “Investor” and collectively, the “Investors”).
LEASELease • March 20th, 2013 • Aratana Therapeutics, Inc. • Kansas
This Lease (the “Lease”) is made and entered into effective as of the 1st day of September 2011, by and between MPM Heartland House, LLC, a limited liability company organized under the laws of the State of Delaware (“Landlord”) and Aratana Therapeutics, Inc., a corporation organized under the laws of the Delaware (“Tenant”).
KANSAS BIOSCIENCE RESEARCH AND DEVELOPMENT (R&D) VOUCHER PROGRAM GRANT AGREEMENTGrant Agreement • March 20th, 2013 • Aratana Therapeutics, Inc. • Kansas
This Research and Development Voucher Grant Agreement (“Agreement”) dated as March 6, 2012 (the “Effective Date”) is by and between the Kansas Bioscience Authority, 10900 S. Clay Blair Blvd., Olathe, Kansas 66061 (the “KBA”) and Aratana Therapeutics, Inc., 1901 Olathe Blvd., Kansas City, KS 66103 (the “Grantee”), collectively the “Parties.”
ADMINISTRATIVE SERVICES AGREEMENTAdministrative Services Agreement • March 20th, 2013 • Aratana Therapeutics, Inc. • Massachusetts
This Administrative Services Agreement (this “Agreement”), dated as of February 19, 2013 is entered into between MPM Asset Management LLC, a Delaware limited liability company (“MPM”), and Aratana Therapeutics, Inc., a Delaware corporation (the “Company”).
SERVICES AGREEMENTServices Agreement • March 20th, 2013 • Aratana Therapeutics, Inc. • Massachusetts
SERVICES AGREEMENT effective as of January 1, 2011 among Aratana Therapeutics, Inc. (the “Company”) and MPM Asset Management LLC (“MPM”).
ARATANA THERAPEUTICS, INC. STOCK OPTION AGREEMENT (2010 EQUITY INCENTIVE PLAN)Stock Option Agreement • March 20th, 2013 • Aratana Therapeutics, Inc.
Pursuant to its 2010 Equity Incentive Plan, as amended (the “Plan”), ARATANA THERAPEUTICS, INC. (the “Company”), hereby grants to you (the “Participant”) an option to purchase the number of shares of the Company’s Common Stock set forth below (the “Option”). Capitalized terms used and not otherwise defined herein shall have the meanings given to such terms in the Plan, a copy of which is attached hereto as Attachment 1.
